128 related articles for article (PubMed ID: 20354459)
1. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.
Bedikian AY; Richards J; Kharkevitch D; Atkins MB; Whitman E; Gonzalez R
Melanoma Res; 2010 Jun; 20(3):218-26. PubMed ID: 20354459
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
Gonzalez R; Hutchins L; Nemunaitis J; Atkins M; Schwarzenberger PO
Melanoma Res; 2006 Dec; 16(6):521-6. PubMed ID: 17119453
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: Allovectin-7, Vical.
Galanis E
Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
[TBL] [Abstract][Full Text] [Related]
8. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
Rini BI; Selk LM; Vogelzang NJ
Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
[TBL] [Abstract][Full Text] [Related]
10. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
Doukas J; Rolland A
Cancer Gene Ther; 2012 Dec; 19(12):811-7. PubMed ID: 23037806
[TBL] [Abstract][Full Text] [Related]
12. Immunologic therapy targeting metastatic melanoma: allovectin-7.
Chowdhery R; Gonzalez R
Immunotherapy; 2011 Jan; 3(1):17-21. PubMed ID: 21174553
[TBL] [Abstract][Full Text] [Related]
13. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
15. Velimogene aliplasmid.
Soares HP; Lutzky J
Expert Opin Biol Ther; 2010 May; 10(5):841-51. PubMed ID: 20367461
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
17. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for head and neck cancer.
Gleich LL
Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
[TBL] [Abstract][Full Text] [Related]
19. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
20. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
